D
deleted4401
There is a NYTimes article these weekend on the lack of use of Bexaar and Zevalin for lymphoma. The article makes it seem like there are indications for it that are being ignored by med-oncs or only used as a last resort after the disease is found to be refractory to chemo + Rituxan. It seems to indicate that a med-onc has to 'refer out' to a nuc med or rad onc, and that they are reluctant to do so, because they make money from chemo administration, but none from Zevalin/Bexaar.
In the context of what we've been discussing - e.g. being primary oncologists - I guess here is an example of where we are losing an opportunity to possibly treat patients more effectively and losing a potential source of income.
I'm still not sure I'm willing to deal with the headaches of an inpatient service, but as radioimmunotherapeutics increase in quantity and efficacy, we may have to go there
-S.
In the context of what we've been discussing - e.g. being primary oncologists - I guess here is an example of where we are losing an opportunity to possibly treat patients more effectively and losing a potential source of income.
I'm still not sure I'm willing to deal with the headaches of an inpatient service, but as radioimmunotherapeutics increase in quantity and efficacy, we may have to go there
-S.